Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
2/5/25 Revalesio RNS60 for Ischemic Stroke Subscribers Only Subscribers Only Subscribers Only
2/4/25 Cumberland Pharmaceuticals (CPIX) Ifetroban, Cumberland Pharmaceuticals for Duchenne Muscular Dystrophy (DMD) Subscribers Only Subscribers Only Subscribers Only
2/4/25 LEO Anzupgo for Atopic Dermatitis (Eczema) Subscribers Only Subscribers Only Subscribers Only
2/3/25 GH Research (GHRS) GH001 for Major Depressive Disorder (MDD) Subscribers Only Subscribers Only Subscribers Only
1/30/25 Shionogi (4507) S-337395 for Respiratory Syncytial Virus (RSV) Treatment Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
10/16/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/30/2024 Subscribers Only Subscribers Only Progress Update - Development Review
12/02/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
01/13/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
02/13/2025 - 01/13/2025 Subscribers Only Subscribers Only Trial Data - Final Results